Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invicta Diagnostic's basic earnings per share (Basic EPS) for the
six
months ended in Mar. 2026 was ₹0.79.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹3.97.
Invicta Diagnostic's EPS without NRI for the
six
months ended in Mar. 2026 was ₹0.79.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 3.97.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Invicta Diagnostic EPS (Basic) Related Terms
Invicta Diagnostic EPS (Basic) Historical Data
* Premium members only.
The historical data trend for Invicta Diagnostic's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Invicta Diagnostic's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹3.97
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic (NSE:INVICTA) has a EPS (Basic) of ₹3.97 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Invicta Diagnostic and its competitors.
Is Invicta Diagnostic's EPS (Basic) too high?
Invicta Diagnostic's current EPS (Basic) is ₹3.97. Overall, Invicta Diagnostic has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Invicta Diagnostic's EPS (Basic) compare to TMO and DHR?
Invicta Diagnostic's EPS (Basic) of ₹3.97 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Diagnostics & Research company?
A good EPS (Basic) depends on the Medical Diagnostics & Research industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Invicta Diagnostic and its competitors. Invicta Diagnostic's current EPS (Basic) is ₹3.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invicta Diagnostic stock overvalued right now?
Invicta Diagnostic (NSE:INVICTA) has a current EPS (Basic) of ₹3.97. The current EPS (Basic) is ₹3.97. Invicta Diagnostic's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Invicta Diagnostic (NSE:INVICTA), the current EPS (Basic) is ₹3.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invicta Diagnostic Ltd is engaged in the business of medical and diagnostic services and operates diagnostic centres providing medical testing and allied healthcare services in the Mumbai Metropolitan Region. The Company runs a diagnostic chain comprising seven diagnostic centres and one centralised laboratory across MMR in Maharashtra and operates under a hub and spoke model with a flagship hub in Thane, additional hub centres, spoke centres, and a centralised laboratory. Its service offerings include radiology and imaging, pathology and clinical laboratory tests, teleradiology, and services such as ultrasound, X Ray, CT scan, MRI scan, PET scan, and cardiac diagnostics, with patient convenience supported through home sample collection, house calls, and multiple report delivery options.
22GF Score
Get the complete analysis for NSE:INVICTA
EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INVICTA has been successfully added to your 
